exRNAdisease

Entry Detail

---



General Information

Database ID: exR0269524 RNA Name: hsa-miR-214-3p RNA Type: miRNA Chromosome: chr1 Starnd: - Coordinate: Start Site(bp): 172138816 End Site(bp): 172138837 External Links: hsa-miR-214-3p

Disease Information

Disease Name: Multiple Sclerosis Disease Category: Nervous System Diseases MeSH ID: D009103 Type: Diseases Category/Nervous System Diseases Alias: Sclerosis, Multiple//Sclerosis, Disseminated//Disseminated Sclerosis//MS (Multiple Sclerosis)//Multiple Sclerosis, Acute Fulminating

Expression Detail

GEO ID: GSE140106 Description: Serum exosome microRNAs predict multiple sclerosis disease activity after fingolimod treatment Experimental Design: Fingolimod treatment Case Disease Type: Multiple Sclerosis Case Disease SubType: NA Case Sample: Fingolimod treated Multiple Sclerosis Control Sample: Untreated Number of Case: 27 Number of Control: 27 Number of Samples: 54

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand MTMR12 chr5 32226994 32312987 - AP3M1 chr10 74120255 74151063 - AMER1 chrX 64185117 64205708 - GDI1 chrX 154436913 154443467 + RPUSD1 chr16 784974 788397 - SMG5 chr1 156249224 156282825 - DHX36 chr3 154272546 154324487 - PIP5K1C chr19 3630183 3700479 - C19orf47 chr19 40319536 40348527 - MTMR3 chr22 29883155 30030866 + ABHD2 chr15 89087459 89202355 + MAPKAPK2 chr1 206684944 206734283 + RHPN1 chr8 143368876 143384221 + HDLBP chr2 241227264 241317061 - ARHGAP35 chr19 46860997 47005077 + YWHAB chr20 44885702 44908532 + WDR5 chr9 134135365 134159968 + RPS6KA1 chr1 26529761 26575030 + JPT1 chr17 75135248 75168281 - SEC61A1 chr3 128051641 128071683 + TMEM161B chr5 88189633 88269476 - NECTIN1 chr11 119623408 119729200 - SOX11 chr2 5692384 5701385 + MYH9 chr22 36281277 36388067 - RAB15 chr14 64945814 64973226 - PLAGL2 chr20 32192504 32207743 - TGIF2 chr20 36573488 36593950 + NRIP1 chr21 14961235 15065936 - LYSMD2 chr15 51723011 51751585 - KMT2D chr12 49018975 49059774 - miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0000540 chr14 55799534 55821940 + hsa_circ_0001168 chr20 47691321 47707559 + hsa_circ_0001146 chr20 34241449 34246936 - hsa_circ_0000799 chr17 65941524 65972074 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC008040.1 chr3 169939353 169966734 - AC010442.1 chr5 466124 473098 - AC016876.2 chr17 7581964 7584086 - AC068790.9 chr12 124085761 124088598 + AC109460.3 chr16 28974804 28990775 + ADAMTSL4-AS1 chr1 150560202 150574552 - AL031282.2 chr1 1702736 1737688 - AL160006.1 chr1 110058340 110062555 + EPB41L4A-AS1 chr5 112160526 112164818 + FGD5-AS1 chr3 14920347 14948424 - LINC00665 chr19 36313067 36331770 - LINC01535 chr19 37251885 37265535 + MIR17HG chr13 91347820 91354579 + NEAT1 chr11 65422774 65445540 + POLR2J4 chr7 43940895 44019175 - SNHG16 chr17 76557764 76565348 + STAG3L5P-PVRIG2P-PILRB chr7 100336104 100367831 + XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE140106 Sample Source: Blood Source Fraction: Exosome Platform: GPL11154 Method: NGS Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1907 Sample treatment protocol: Exosomes were isolated from 1 mL RNase A (37 °C for 10 min; 100 ng/ml; Qiagen, Australia) treated serum, by size exclusion chromatography (qEV iZONE Science). RNA Extract protocol: Serum exosomes were processed for RNA extraction using the Plasma/Serum Circulating & Exosomal RNA Purification Mini Kit (Norgen Biotek, Cat. 51000) according to the manufacturer's protocol. RNA library preparation protocol: Exosome RNA sequencing libraries were then constructed using the NEBNext Multiplex Small RNA Library Prep Kit for Illumina (BioLabs, New England) according to the manufacturer's instructions.

Reference

PMID: 31721043 Title: Serum Exosome MicroRNAs Predict Multiple Sclerosis Disease Activity after Fingolimod Treatment Author: Ebrahimkhani S, Beadnall HN, Wang C, Suter CM, Barnett MH, Buckland ME, Vafaee F Journal: Mol Neurobiol. 2020 Feb;57(2):1245-1258. Description: we sought the possible utility of serum exosome microRNAs as biomarkers for disease activity in multiple sclerosis patients in response to fingolimod therapy.